Hercerptin, shaken not stirred
Treating tumors with the monoclonal antibody herceptin can bypass drug resistance problems.
Mar 25, 2002
Tumors can develop drug resistance to single angiogenic factor treatments, and with the exception of a cocktail of multiple anti-angiogenic drugs, there are few other treatments available to overcome this problem. But in March 21
Izumi
"As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic...